484 completed, 189 unknown, 87 terminated, 78 recruiting. 937 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 937 | Completed 484, Unknown 189, Terminated 87, Recruiting 78, Not yet recruiting 37, Withdrawn 37, Active not recruiting 20, Enrolling by invitation 4, Suspended 1 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA iron sulfate - Iron Deficiency Anemia | Phase 4 | Not yet recruiting | Loma Linda University | 100 | 2026-12-01 | 2026-07-10 |
| Sucrosomial Vs Intravenous Iron for Preoperative Anemia Treatment with oral sucrosomial iron, Treatment with intravenous iron - Anemia, Iron Deficiency Anemia | Phase 4 | Withdrawn | University of Rochester | 2026-12-01 | 2026-10-06 | |
| MACE and BTK Inhibitors ibrutinib, Acalabrutinib, Zanubrutinib - Hematologic Cancer, MACE | Phase 4 | Not yet recruiting | University Hospital, Caen | 10000 | 2026-12-01 | 2026-11-06 |
| Hematological Safety of Dipyrone Versus Paracetamol After Dental Extractions Dipyrone administration, Paracetamol (drug), blood sampling - Hematologic Test, Agranulocytosis | Phase 4 | Recruiting | Matheus Furtado de Carvalho | 50 | 2026-11-13 | 2026-11-06 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. - Multiple Myeloma in Relapse | Phase 4 | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-21 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| IRONCARE: Iron Treatment in Older Patients With Hip Fractures Ferric Derisomaltose, Oral Iron (Ferrous sulphate), Placebo IV - Hip Fracture, Anemia | Phase 4 | Not yet recruiting | University of Aarhus | 528 | 2026-10-01 | 2026-06-24 |
| The Safety of Simplified Tranexamic Acid Regimen Tranexamic Acid (TXA) - Trauma Coagulopathy, Hemorrhage | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2026-10-01 | 2026-10-09 |
| Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2026-10-01 | 2026-09-18 |
| Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related | Phase 4 | Withdrawn | Emory University | 2026-09-01 | 2026-10-19 | |
| Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer Ferric Carboxymaltose (FCM), Iron Sucrose. - Gastric Cancer (GC), Iron Deficiency Anemia (IDA) | Phase 4 | Not yet recruiting | Zhaojian Niu,MD | 160 | 2026-08-01 | 2026-08-19 |
| Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | Phase 4 | Not yet recruiting | University of Mississippi Medical Center | 400 | 2026-08-01 | 2026-07-06 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD) | Phase 4 | Recruiting | Swiss Tropical & Public Health Institute | 120 | 2026-07-27 | 2026-10-05 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| The Effect Of Lisinopril On Polycythemia Lisinopril Tablets - Polycythemia | Phase 4 | Recruiting | Mayo Clinic | 30 | 2026-07-01 | 2026-08-21 |
Showing 20 of 937. Sign in to see all of them.
Anemia (195) · Anemia, Iron-Deficiency (102) · Hemophilia A (67) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (60) · Multiple Myeloma (54) · Leukemia, Myeloid, Acute (41) · Anemia, Sickle Cell (38) · Renal Insufficiency, Chronic (34) · Neoplasms (32) · Hemostatic Disorders (30) · Iron Deficiencies (30) · Leukemia (30) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Febrile Neutropenia (28) · Neutropenia (28)
Hemic and Lymphatic Diseases (937) · Neoplasms (272) · Pathological Conditions, Signs and Symptoms (265) · Neoplasms by Histologic Type (244) · Immune System Diseases (231) · Pathologic Processes (225) · Hemorrhagic Disorders (206) · Anemia (189) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (180) · Genetic Diseases, Inborn (175) · Immunoproliferative Disorders (154) · Lymphoproliferative Disorders (154) · Nutritional and Metabolic Diseases (147) · Leukemia (143)
ferric carboxymaltose (45) · Dexamethasone (36) · Cytarabine (34) · Cyclophosphamide (27) · ferrous sulfate (27) · Factor VIII (24) · Epoetin Alfa (22) · Methotrexate (21) · Vincristine (21) · Sodium Chloride (20) · epoetin beta (20) · Iron (17) · Iron-Dextran Complex (17) · Ferric Oxide, Saccharated (16) · Idarubicin (16)
Novartis Pharmaceuticals (36) · Hoffmann-La Roche (27) · PETHEMA Foundation (20) · Peking Union Medical College Hospital (20) · Amgen (17) · Pfizer (17) · Ain Shams University (10) · Institute of Hematology & Blood Diseases Hospital, China (10) · Baxalta now part of Shire (9) · Bayer (8) · Shandong University (7) · Watson Pharmaceuticals (7) · Assiut University (6) · AstraZeneca (6) · Goethe University (6)
United States (210) · China (148) · Spain (76) · Germany (61) · France (58) · Italy (56) · United Kingdom (49) · Canada (38) · Egypt (38) · India (30) · Belgium (26) · Poland (25) · Brazil (23) · Netherlands (23) · South Korea (22)
Dieter Hoelzer, MD,PhD (4) · Sanz Miguel Angel, Dr (4) · Xiaofan Zhu, MD (4) · Bing Bing, PhD (3) · Bing Han, PhD (3)
PMID 36791280, PMID 41114449, PMID 18328118, PMID 34932836, PMID 36064577, PMID 18828899, PMID 19005182, PMID 19144982, PMID 19208097, PMID 22442346, PMID 22493293, PMID 23024237, PMID 24363761, PMID 24923295, PMID 26504182, PMID 27561722, PMID 27881371, PMID 28751559, PMID 28945881, PMID 34710946, PMID 10049409, PMID 10100293, PMID 10231138, PMID 10583235, PMID 1090310, PMID 11057854, PMID 11796024, PMID 11863096, PMID 12045120, PMID 12084168, PMID 12627513, PMID 14585365, PMID 14616423, PMID 14719181, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15257960, PMID 15500369, PMID 15661401, PMID 15770833, PMID 15824508, PMID 15953714, PMID 16096770, PMID 16110027, PMID 16177289, PMID 16197446, PMID 16273116, PMID 16329022, PMID 1640190
2009 (8), 2018 (7), 2023 (7), 2014 (6), 2016 (6), 2005 (4), 2015 (4), 2008 (3), 2019 (3), 2017 (2), 2004 (1), 2025 (1), I01CX001449 (1), P01CA128115 (1), P30AI060354 (1)